- Clone
- 9G1B30 (See other available formats)
- Regulatory Status
- RUO
- Other Names
- TIR domain-containing adapter molecule 2, TRIF-related adapter molecule (TRAM), Toll-like receptor adaptor protein 3, Toll/interleukin-1 receptor domain-containing protein
- Isotype
- Mouse IgG2a, κ
- Ave. Rating
- Submit a Review
- Product Citations
- publications
Cat # | Size | Price | Quantity Check Availability | Save | ||
---|---|---|---|---|---|---|
659402 | 100 µg | 265 CHF |
TICAM-2, also known as TRIF-related adaptor molecule (TRAM), is a TIR domain containing protein that was found to act as an adaptor molecule during LPS-induced innate immune response. Upon infection by Gram-negative bacteria, TLR4 specifically recognizes LPS and leads to the dimerization of the cytoplasmic TIR domains. The activated TLR4 subsequently recruits the adaptor protein complex containing both TICAM-1 and TICAM-2, resulting in the activation of IFN response factors and production of pro-inflammatory cytokines. In this signaling cascade, TICAM-2 is essential for bridging the interaction between TLR4 and TICAM-1. TICAM-2 is also involved in the regulation of the IL-18 signaling pathway, acting as a sorting adaptor that recruits MYD88 from the cytosol to the membrane region upon activation of IL-1/IL-18 receptors.
Product DetailsProduct Details
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- Full length human TICAM-2 recombinant protein expressed in E. coli.
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
- Preparation
- The antibody was purified by affinity chromatography.
- Concentration
- 0.5 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C.
- Application
-
WB - Quality tested
- Recommended Usage
-
Each lot of this antibody is quality control tested by Western blotting. For Western blotting, the suggested use of this reagent is 0.5 - 2.0 µg per ml. It is recommended that the reagent be titrated for optimal performance for each application.
- Application Notes
-
Daudi cells were selected as a negative control for antibody testing due to the cell line’s low expression level of the mRNA encoding TICAM2 (source: Human Protein Atlas).
- RRID
-
AB_2563252 (BioLegend Cat. No. 659402)
Antigen Details
- Structure
- 235 amino acids encode a protein with a predicted MW of 27 kD. Contains a TIR domain responsible for mediating the physical interaction with TLR4 and TICAM-1.
- Distribution
-
Cytoplasm, golgi apparatus, endosome, cell membrane, and endoplasmic reticulum.
- Function
- TICAM-2 acts as a sorting adaptor molecule that transduces TLR4 signaling to TICAM-1 and regulates MYD88-independent pathway in response to LPS stimulation.
- Interaction
- Interacts with TRAF6, MYD88, TLR4, IL1R1, IL1RAP, IRAK2, IRAK3, TICAM1, IRF3, and IRF7.
- Cell Type
- Dendritic cells
- Biology Area
- Cell Biology, Immunology, Innate Immunity, Neuroscience, Signal Transduction
- Antigen References
-
1. Enokizono Y, et al. 2013. Proc. Natl. Acad. Sci. USA. 110:19908.
2. Ohnishi H, et al. 2012. PLoS One. 7:e38423.
3. Wu B, et al. 2011. Dev. Comp. Immunol. 35:764.
4. Seya T, et al. 2005. Int. J. Biochem. Cell Biol. 37:524.
5. Vogel SN, et al. 2003. Mol. Interv. 3:466.
6. Oshiumi H, et al. 2003. J. Biol. Chem. 278:49751. - Gene ID
- 353376 View all products for this Gene ID
- UniProt
- View information about TICAM-2 on UniProt.org
Related Pages & Pathways
Pages
Related FAQs
Other Formats
View All TICAM-2 Reagents Request Custom ConjugationDescription | Clone | Applications |
---|---|---|
Purified anti-TICAM-2 (TRAM) | 9G1B30 | WB |
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.
-
Purified anti-TICAM-2 (TRAM)
Whole cell lysates (15 µg protein) from Daudi (negative cont...
Follow Us